Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated)

NACompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Wild-type Amyloid Cardiopathy
Interventions
PROCEDURE

electromyogram

Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.

Trial Locations (3)

31059

CHU de Toulouse, Toulouse

33076

CHU de Bordeaux, Bordeaux

44093

CHU de Nantes, Nantes

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT04828928 - Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated) | Biotech Hunter | Biotech Hunter